Netherlands· NL-deeddd03f2fe
Lamivudine Sandoz 150 mg, filmomhulde tabletten
A lamivudine product containing lamivudine 0,2-water, registered in Netherlands by Sandoz B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Lamivudine is registered in 17 of 19 countries.
Countries holding a registration under ATC J05AF05 (lamivudine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Lamivudine · ATC J05AF05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lamivudine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $2.42 in France to $7.71 in Switzerland — a ×3.2 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lamivudine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.71
- IT Italy$6.75
- FR France$2.42
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- LAMIVUDINE 0,2-WATER
- Manufacturer
- Sandoz B.V.
- Country
- Netherlands (NL)
- ATC code
- J05AF05
- ATC class
- Lamivudine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id111999
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
207 interactions on record for lamivudine.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lamivudine · interactions on record
207 records
- 6 severe
- 36 moderate
- 165 info
Most severe, free to view
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lamivudine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEPIVIRViiV Healthcare Company
- CzechiaEPIVIRViiV Healthcare BV, Amersfoort
- BelgiumDutrebis 150 mg - 300 mgMerck Sharp & Dohme
- SpainEPIVIR 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- FinlandEpivirOrifarm Oy
- FranceEPIVIR 150 mg, comprimé pelliculéVIIV HEALTHCARE UK (ROYAUME-UNI)
- IcelandEpivirViiV Healthcare BV
- PolandEpivirViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 12 EEA countries. Names it is sold under:
- Austria · Lamivudin Sandoz
- Cyprus · Lamivudine Normon
- Germany · Lamivudin Aurobindo, Lamivudin Mylan
- Spain · Lamivudina Accord, Lamivudina Aurovitas
- France · Lamivudine Arrow, Lamivudine Sandoz
- United Kingdom (Northern Ireland) · Lamivudine Amarox, Lamivudine Generics
- Iceland · Epivir, Lamivudine Teva
- Italy · Lamivudina Aurobindo, Lamivudina Aurobindo Italia
- Liechtenstein · Epivir, Lamivudine Teva
- Norway · Epivir, Lamivudine Teva
- Poland · Lamivudine Aurovitas
- Portugal · Lamivudina Aurobindo, Lamivudina Farmoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b4532b42-31af-4955-936e-ef772ac82d9f GET /v1/drugs/b4532b42-31af-4955-936e-ef772ac82d9f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h111999_smpc_en.pdf",
"strength": null,
"atc_label": "Lamivudine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg111999",
"excipients": [
"CROSPOVIDON (E 1202)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"ISOMALT (E 953)",
"MACROGOL 400",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYSORBAAT 80 (E 433)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"LAMIVUDINE 0,2-WATER"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h111999_piluk.pdf",
"authorised_at": "2013/08/22",
"procedure_number": "NL/H/2655/002",
"dispensing_status": "Uitsluitend recept",
"registration_number": "111999",
"additional_monitoring": "N"
}See everything about lamivudine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.